Current Affairs - National - Discussion

Panacea Biotec developed DengiAll, India's first indigenous dengue vaccine, which is currently in Phase 3 trials. The vaccine targets all four dengue virus serotypes and is being tested across 19 sites with over 10,000 participants. This development is crucial as dengue remains a significant public health challenge in India, transmitted by Aedes mosquitoes. The successful trial of DengiAll could provide a vital tool in combating this widespread disease.